Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V
Progresses Acromegaly programme towards clinic
13-May-2011 -
Syntaxin announced a manufacturing agreement with SynCo Bio Partners B.V. Under the agreement, SynCo will manufacture SXN101959, Syntaxin’s lead internal candidate for Acromegaly, discovered from its Targeted Secretion Inhibitor (TSI) platform. Acromegaly is a chronic and debilitating disease ...
acromegaly
growth hormones
hypersecretion